Drug Profile
Camptothecin liposomal - Therapeutics 2000
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Therapeutics 2000
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 23 Nov 2001 No-Development-Reported for Lung cancer in USA (Inhalation)
- 02 Nov 1998 New profile
- 02 Nov 1998 Preclinical development for Lung cancer in USA (Inhalation)